Multicenter Phase II Study of a New Effective S-1 and Irinotecan Combination Schedule in Patients with Unresectable Metastatic or Recurrent Colorectal Cancer

Yutaka Ogata¹,², Takaho Tanaka³, Yoshito Akagi², Nobuya Ishibashi¹, Yoshiaki Tsuji⁴, Keiko Matono⁴, Makoto Isobe⁵, Susumu Sueyoshi⁶, Atsushi Kaibara³ and Kazuo Shirouzu²

Kurume Surgical and Clinical Oncology Group, ¹Department of Surgery, Kurume University Medical Center, Kurume, Japan. ²Department of Surgery, Kurume University Hospital, Kurume, Japan. ³Department of Surgery, Social Insurance Tagawa Hospital, Tagawa, Japan. ⁴Department of Surgery, Asakura Medical Association Asakura hospital, Asakura, Japan. ⁵Department of Surgery, Social Insurance Kurume Daiichi Hospital, Kurume, Japan. ⁶Department of Surgery, Omuta City General Hospital, Omuta, Japan. Corresponding author email: yogata@med.kurume-u.ac.jp

Abstract

Introduction: This multicenter phase II study determined the efficacy and safety of new daily oral S-1 and weekly irinotecan (CPT-11) combination schedule in patients with previously untreated advanced or recurrent colorectal cancer.

Patients and methods: Patients received first-line chemotherapy comprising S-1 80 mg/m²/day given on days 3 to 7, 10 to 14, and 17 to 21 and 60 mg/m² CPT-11 administered intravenously on days 1, 8, and 15 of a 28-day cycle.

Results: A total of 45 eligible patients were enrolled in this study. The overall response rate was 48.9%. Median progression-free survival and median overall survival was 8.1 months and 20.9 months, respectively. The rates of grade 3 or 4 toxicity were as follows: neutropenia, 8.9%; anemia, 4.4%; anorexia, 6.7%; and diarrhea, 6.7%.

Conclusions: This new S-1 and irinotecan combination schedule appeared to be an effective, well-tolerated, and convenient regimen in patients with advanced colorectal cancer as compared with conventional regimens such as FOLFIRI and IRIS.

Keywords: advanced colorectal carcinoma, first-line chemotherapy, irinotecan, multicenter phase II study, metronomic chemotherapy, S-1
Introduction
Irinotecan (CPT-11) is a key drug in the management of metastatic colorectal cancer as demonstrated by several randomized studies indicating a survival benefit. It was shown that the response rate to CPT-11 was 11% to 25% in patients with advanced colorectal cancer refractory to 5-fluorouracil (5-FU)-based chemotherapy.1,2 These findings implied a lack in tumor cross-resistance between the two agents CPT-11 and 5-FU. Moreover, favorable results from combination chemotherapy using CPT-11 and 5-FU/leucovorin (LV) for advanced colorectal cancer have been reported.3,4 A CPT-11 and infusion plus bolus 5-FU/LV regimen (FOLFIRI) with or without biologics has been recommended as first-line therapy for advanced colorectal cancer. FOLFOX regimens which add oxaliplatin to intravenous 5-FU/LV have also been recommended.5 These regimens consist of the conventional maximum tolerated dosage (MTD) of CPT-11 and 5-FU. Consequently, grade 3 or worse adverse effects are not uncommon. Moreover, administration of infusion 5-FU is becoming more complex because of the need for vascular access devices and a portable delivery system.

Dihydropyrimidine dehydrogenase (DPD)-inhibitory fluoropyrimidine (DIF) compounds such as UFT and S-1 have been developed in an attempt to resolve the issue of the rapid reduction in 5-FU by DPD. S-1 is an oral DIF developed by Taiho Pharmaceutical Co., Ltd. (Tokyo, Japan) that combines tegafur with two 5-FU modulators, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1.6 Tegafur, a prodrug of 5-FU, is converted to 5-FU mainly in the liver and in the tumor cells. CDHP, a reversible inhibitor of DPD, suppresses the degradation of 5-FU, thereby maintaining high concentrations of 5-FU in plasma and the tumor cells.6,7 CDHP also decreases the cardio- and neurotoxic effects by reducing the production of F-beta-alanine (FBAL), the main catabolite of 5-FU.8,9 After peroral administration, Oxo is selectively distributed to the small and large bowels. High concentrations of Oxo in these organs inhibit the phosphorylation of 5-FU to fluoropyrimidine monophosphate, catabolized by orotate phosphoribosyltransferase within the gastrointestinal mucosal cells, thereby reducing the incidence of diarrhea.10 DPD is approximately 180 times more potent than the DPD inhibitor uracil, which is a component of UFT. Thus, S-1 results in higher concentrations of 5-FU in the blood and tumor tissue than UFT.11 Because S-1 is thought to be more potent than UFT with respect to the biochemical modulation effect, one might expect a stronger antitumor effect of S-1.

In phase II trials of S-1 as a single agent in patients with advanced colorectal cancer, response rates ranging from 19% to 39% have been reported.12-14 These studies also demonstrated that S-1 had good compliance in patients with advanced colorectal cancer treated on an outpatient basis. Several regimens combining S-1 and CPT-11 were subsequently developed.15-19 Goto et al15 conducted a phase II study consisting of 150 mg/m^2 of CPT-11 given on day 1 and 40 mg/m^2 of S-1 twice daily on days 1 to 14 of a 21-day cycle to assess efficacy and safety. They concluded that the combined treatment was a promising regimen, offering benefits in terms of safety and survival as compared with conventional regimens in patients with advanced colorectal cancer. Muro et al20 reported a noninferiority of IRIS regimen consisting of 125 mg/m^2 of CPT-11 given on days 1 and 15 with 40 mg/m^2 of S-1 twice daily on days 1 to 14 of a 28-day cycle to the FOLFIRI regimen in a phase III study as second-line therapy.

Conventional cytotoxic chemotherapeutics affect the endothelium of the growing tumor vasculature in addition to affecting the proliferating cancer cells and various types of normal cells.21 The antiangiogenic effects of chemotherapy would seem to be optimized by administering a comparatively low dose according to a more frequent (daily, several times a week, or weekly) or continuous schedule, with no extended interruptions, which is sometimes referred to as metronomic chemotherapy.22 This would also have the advantage of being less acutely toxic, therefore, making more prolonged treatments hypothetically possible. Thus, peroral fluoropyrimidine on a daily schedule such as S-1 would be a reasonable metronomic chemotherapy. High rates of grade 3 or 4 toxicities generally can necessitate temporary suspension of the chemotherapy, especially when CPT-11 is given at a high dosage biweekly or triweekly schedule similar to Goto’s regimen13 and Muro’s regimen.20 This might not allow the metronomic advantage of daily peroral fluoropyrimidine to be realized in combination with CPT-11. We, therefore, postulate that a new
combination therapy of low-dose and weekly CPT-11 with daily S-1 could realize the advantages of metro-
nomic administration probably having an antiangi-
genic effect in addition to an antiproliferation effect.
Ogata et al conducted a phase I study to assess the
recommended doses of weekly CPT-11 and S-1 com-
bination therapy, which recommended a CPT-11
dose of 60 mg/m² on days 1, 8, and 15 with 40 mg/m²
of S-1 twice daily on days 3 to 7, days 10 to 14, and
on days 17 to 21 of a 28-day cycle. We report the
results of this phase II study to validate the antitumor
efficacy and safety of weekly CPT-11 combined with
daily S-1 as new combination schedule representing
a metronomic advantage in addition to a cytotoxic
effect.

Patients and Methods

Eligibility
This was a nonrandomized, open-label, multicenter
phase II study. Eligible patients had histological find-
ings of colorectal adenocarcinoma that was either
unresectable, locally advanced, metastatic, or recurrent
disease. They also had no prior chemotherapy, major
surgery, or radiation therapy within 2 weeks of begin-
nning treatment and measurable tumors with at least one
lesion having dimensions > 10 mm in longest diam-
eters. A life expectancy of 3 months and a performance
status (PS) according to an Eastern Cooperative Group
(ECOG) scale of 0 to 1 was mandated along with ade-
quate bone marrow function (leukocytes 4000 per mm³,
granulocytes 1500/mm³, platelets 100000 per mm³),
adequate liver function (bilirubin 1.5 mg/dL), adequate
renal function (creatinine 1.1 mg/dL), no serious or
uncontrolled concurrent medical illness, and no other
active malignancy. Postoperative adjuvant chemother-
apy excluding regimens including CPT-11 or S-1 was
allowed. Patients were required to be 20 years of age
or greater and 75 years of age or less and not pregnant.
All patients were informed of the investigational nature
of this treatment and gave their fully informed written
consent.

The study has been approved by the ethics
committee of Kurume University and each institutional
ethical committee.

Treatment protocol
CPT-11 was administered by infusion intravenously
over 90 minutes once weekly for three consecutive
weeks followed by one week of rest in 4-week
treatment cycles. S-1 was available as capsules
containing 20 or 25 mg of tegafur. S-1 was given
orally twice daily on days 3 to 7, 10 to 14, and 17 to
21. Patients were assigned one of the following doses
to be taken within an hour after breakfast and sup-
ner on the basis of body surface area (BSA): 40 mg
(BSA < 1.25 m²), 50 mg (1.25 m² ≤ BSA < 1.50 m²),
or 60 mg (BSA ≥ 1.50 m²). Cycles were repeated
every 4 weeks until disease progressed.

The CPT-11 administration was temporarily sus-
pended for grade 2 or higher mucositis, any grade
of diarrhea, other nonhematological toxicity grade 3
or higher, or for leukocytes < 3000/mm³, granulo-
cytes < 1500/mm³, or platelets < 100,000/mm³. The
S-1 administration was also temporarily suspended
for grade 2 or higher diarrhea, grade 2 or higher
mucositis, other nonhematological toxicity grade 3
or higher, or for leukocytes < 2000/mm³, granulo-
cytes < 1000/mm³, or platelets < 75,000/mm³. The
therapy was alternatively reinstituted using reduced
dosages after all toxicity had recovered if
leukocytes < 2000/mm³, granulocytes < 1000/mm³,
platelets < 50000/mm³, or grade 3 or higher non-
hematological toxicity (excluding nausea/vomiting
and general fatigue) was noted during the cycle or
if the treatment delay was longer than 14 days. The
dosage of CPT-11 was reduced by 10 mg/m² for sub-
sequent courses, and the 60 mg, 50 mg, and 40 mg
doses of S-1 were reduced in subsequent courses to
50 mg, 40 mg, and 25 mg twice daily, respectively.
Once lowered, the doses of S-1 and irinotecan were
not increased. All treatment was performed on an
outpatient basis.

Evaluation
Within 2 weeks before initiating the chemotherapy,
all patients were assessed by a physical examination,
laboratory analyses, ECG, and computed tomography
(CT) scans of the abdomen and chest to define the
extent of disease. Complete blood cell counts with
platelet and differential counts were recorded weekly
during chemotherapy, and serum chemistries were
repeated once or twice within every treatment cycle.
Subjective symptoms, body weight, physical exami-
nation, performance status, and all adverse effects
were recorded before each treatment course. Mea-
surement of serum tumor marker carcinoembryonic
antigen (CEA) level was performed at least once every 4 weeks.

Measurable lesions were reassessed every 8 weeks or 2 chemotherapy cycles using CT scan that allowed retrospective and independent evaluation. The response rate was assessed every 8 weeks using the RECIST criteria version 1.0. All tumor measurements were reviewed and confirmed by an independent panel of radiologists. The overall survival (OS) and the progression-free survival (PFS) were calculated as the time from the first infusion until death or until disease progressed using the Kaplan-Meier product-limit method.

Adverse reactions were evaluated according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0. Relative dose intensity was determined for up to six courses of treatment per patient.

### Statistical analysis

Response rates with 5-FU plus LV or with irinotecan as a single agent were approximately 20% in previous clinical trials in patients with advanced colorectal cancer. With a combination of irinotecan, 5-FU, and LV as first-line treatment for advanced colorectal cancer, the response rate was about 40%. We calculated the required sample size for this study on the basis of a target activity level of 40% and a minimum activity level of 20%, with alpha and beta error of 0.15. The required number of patients was estimated to be 41. A stopping rule was included in this study. All data were compiled and analyzed using Statistical Analysis Software (SAS) version 6.12, (SAS Institute, Cary, NC, USA). The exact binomial confidence interval was applied to estimate the response rates.

### Results

#### Patient characteristics

Between April 1, 2006 and October 31, 2007, we enrolled 46 patients with advanced colorectal carcinoma. One patient did not have any measurable tumor. In all, 45 patients met all eligibility requirements. The patients’ characteristics are shown in Table 1. All eligible patients received at least one course of treatment. The average age was 62 years, ranging from 38 to 75 years. Twenty-seven were male, and 18 were female. The PS was 0 in the majority of patients. Thirty-four patients had recurrent tumors.

| Total number of patients | 45 |
|--------------------------|----|
| Age                      | 62 (38–75) |
| Sex                      | 27 Male, 18 Female |
| PS                       | 37 0, 8 1 |
| Primary lesion           | 32 Colon, 13 Rectum |
| Metastases or recurrence | 11 Metastases, 34 Recurrence |
| Adjuvant chemotherapy    | 7 –, 27 + |
| Number of organs involved| 22 1, 13 2, 10 ≥3 |
| Site of metastasis       | 34 Liver, 13 Lung, 14 Lymph nodes, 11 Peritoneum, 2 Primary site, 6 Others |

Among them, twenty-seven patients received prior adjuvant chemotherapy, and the most commonly affected site of metastasis was the liver. One half of patients had more than one organ affected by metastases. Two patients had primary site with metastatic lesions at study entry. The median follow-up time was 21 months. The eligible 45 patients had received a total of 255 treatment cycles (5.7 ± 2.7 courses; range, 1–14 courses).

#### Antitumor efficacy

All eligible 45 patients had at least one measurable lesion. One patient achieved a complete response (CR), while 21 patients achieved partial responses (PR). Seven patients did not respond to chemotherapy and the disease progressed (PD); 16 patients showed a stable disease (SD) condition. The objective response rate was 48.9% with the 95% confidence interval (95% CI) being from 33.7% to 64.2%. The disease control rate was 84.4% with the 95% CI being from 70.5% to 93.5% (Table 2). At a median follow-up time
of 21 months, the median progression-free survival (PFS) time was 8.1 months (range, 1–22 months; 95% CI, 6.2–9.0 months) (Fig. 1), and the median overall survival time (OS) was 20.9 months (range, 2–59 months; 95% CI, 15.5–27.3 months) (Fig. 2).

Adverse effects
A total of 260 treatment cycles were administered to the 45 eligible patients and 1 ineligible patient to define safety profiles. Toxicity is summarized according to the worst grade per patient in Table 3. There were no treatment-related deaths. The most common type of hematological toxicity was neutropenia (leukopenia); however, the incidence of grade 3 or 4 neutropenia was very low (8.7%). The patient with the grade 3 elevation of bilirubin was confirmed to have severe multiple liver metastasis at study entry. The most common types of nonhematological toxicity were anorexia and diarrhea, which were usually mild. Cumulatively, myelosuppression and gastrointestinal toxicity were the most common adverse events but were generally mild. The incidence of grade 3 or 4 toxicity was less than 10% altogether. Treatment was discontinued because of toxicity in 6 of the 46 patients (13%). The reasons for discontinuing treatment were as follows: (1) treatment delay longer than 14 days due to grade 2 neutropenia, (2) treatment delay longer than 14 days due to grade 2 diarrhea, (3) grade 3 confusion due to trouble in stoma care associated with grade 3 diarrhea, (4) patient’s refusal to continue treatment because of grade 3 anorexia, (5) patient’s refusal to continue treatment because of grade 2 diarrhea, and (6) patient’s refusal to continue treatment because of prolonged mild fatigue and nausea.

Relative dose intensity
The administration of CPT-11 was skipped on a few occasions mainly because of grade 2 or 3 neutropenia,
diarrhea, or a patient’s request due to nausea/vomiting, anorexia, or general fatigue. Table 4 lists the amount of CPT-11 and S-1 chemotherapy actually administered, relative to the normal full dosage, in each treatment cycle up to 6th cycle (a total of 219 cycles). The mean relative dose intensity of CPT-11 was 90% with a range from 86% to 94% in each treatment cycle. The mean relative dose intensity of S-1 was 92% with a range from 87% to 97% in each treatment cycle. All patients received the initial doses of irinotecan and S-1 on day 1 and day 3 of the first treatment cycle on an outpatient basis. Three patients were subjected to dosage reduction in CPT-11 and S-1 according to the dosage-reduction criteria. One

![Graph showing overall survival of 45 patients with previously untreated colorectal cancer who received new combination chemotherapy of S-1 and irinotecan. Median progression-free survival was 20.9 months (95% CI, 15.5–27.3 months).](image)

**Table 3. Adverse events (n = 46).**

| Grade (NCI-CTCAE, ver. 3.0) | All grades (%) | Grade 3–4 (%) |
|-----------------------------|----------------|--------------|
| Leukopenia                  |                |              |
| 12                          | 13             | 1            | 0 | 56.5 | 2.2 |
| Neutropenia                 | 10             | 10           | 4 | 0   | 52.2 | 8.7 |
| Thorombocytopenia            | 1              | 0            | 0 | 0   | 2.2  |
| Anemia                      | 4              | 4            | 2 | 0   | 21.7 | 4.3 |
| Anorexia                    | 13             | 6            | 3 | 0   | 47.8 | 6.5 |
| Nausea                      | 7              | 8            | 0 | 0   | 32.6 |
| Vomitting                   | 1              | 3            | 0 | 0   | 8.7  |
| Diarrhea                    | 9              | 7            | 3 | 0   | 41.3 | 6.5 |
| Stomatitis                  | 4              | 1            | 0 | 0   | 10.7 |
| Fatigue                     | 14             | 6            | 0 | 0   | 43.5 |
| Alopecia                    | 15             | 2            | 0 | 0   | 37.0 |
| Confusion                   | 0              | 0            | 1 | 0   | 2.2  | 2.2 |
| Elevation AST/ALT           | 7              | 2            | 0 | 0   | 19.6 |
| Hyperbilirubinemia          | 1              | 0            | 1 | 0   | 4.3  | 2.2 |
| Creatinine                  | 2              | 0            | 0 | 0   | 4.3  |
New combination schedule of S-1 and irinotecan

patient required dosage reduction in CPT-11 because of grade 2 fatigue, and another patient required dosage reduction in S-1 because of grade 1 diarrhea and fatigue.

Poststudy therapy

Among the 45 patients, 30 patients received poststudy chemotherapy, 5 patients received surgery, 1 patient received radiotherapy for intrapelvic recurrent tumor, and 9 patients received best supportive care only. Oxaliplatin-containing regimens were administered to 28 patients (93%). Second-line chemotherapy was administered to 9 patients, third-line chemotherapy to 16 patients, and fourth-line chemotherapy to 5 patients. Bevacizumab was administered to 9 patients, and cetuximab was administered to 2 patients. Surgery for 2 patients with unresectable disease was converted to resection after second-line chemotherapy.

Discussion

Metronomic chemotherapy has been summarized by Kerbel et al as showing that (1) conventional cytotoxic anticancer drugs have antiangiogenic effects that could contribute to their efficacy, and (2) the antiangiogenic effects of chemotherapy seemed to be optimized by administering such drugs metronomically, that is, in small dosages on a frequent schedule (daily, several times a week, or weekly) in an uninterrupted manner. The present phase II study assessed the efficacy and safety of a new S-1 and CPT-11 combination therapy in patients with previously untreated metastatic or recurrent colorectal cancer. Our results showed that the new combination schedule was effective, with a response rate of 48.9%, median PFS of 8.1 months, and median OS of 20.9 months, whereas a total dosage of CPT-11 was relatively low. In previous phase III studies of CPT-11 plus intravenous 5-FU and LV, response rates ranged from 31% to 62%. Median time to progression (TTP) or PFS was 6.7 to 8.7 months, and median OS was 14 to 21.5 months. Although there are limitations in comparing the results of different studies, the response rate, DFS, and OS in our study were similar to those reported in previous studies of CPT-11 plus intravenous 5-FU and LV. Moreover, our results were not inferior to those of the regimen, combination therapies using S-1 and conventional MTD administration of CPT-11, with response rates of 52.5% to 62.5% and with a median PFS of 7.7 to 8.6 months as a first-line therapy (Fig. 3). In these regimens, 80 mg/m² of S-1 was administered at 3.5 days to 4.7 days per week, and CPT-11 was administered at dosage of 32 mg/m² to 50 mg/m² per week and 0.33 times to 0.5 times per week. A key characteristic of our regimen was the frequency in CPT-11 administered 0.75 times per week.

In our preclinical study of metronomic chemotherapy using CPT-11 for colon cancer implanted in nude mice, the metronomic chemotherapy was more effective than the conventional MTD therapy via antiangiogenic effect associated with a consistent inhibition of circulating endothelial progenitor cells (CEPs). Both frequent administration of CPT-11 and S-1 would be reasonable to enhance significant antiangiogenic activity compared with oral S-1 regimens combined with MTD administration of CPT-11, as reported by Munoz et al using combination oral UFT-cyclophosphamide metronomic chemotherapy against breast cancer in mice.

Table 4. Administered dosage of CPT-11 and S-1 as a function of normal full dosage.

| Treatment cycle | No. of patients | CPT-11 dosage administered/normal (mean; %) | Patients receiving >80% of normal CPT-11 dosage (%) | S-1 dosage administered/normal (mean; %) | Patients receiving >80% of normal S-1 dosage (%) |
|-----------------|----------------|---------------------------------------------|-----------------------------------------------|------------------------------------------|-----------------------------------------------|
| 1st             | 45             | 94                                          | 96                                            | 97                                       | 96                                            |
| 2nd             | 43             | 92                                          | 91                                            | 92                                       | 95                                            |
| 3rd             | 39             | 89                                          | 87                                            | 91                                       | 95                                            |
| 4th             | 37             | 86                                          | 84                                            | 91                                       | 95                                            |
| 5th             | 32             | 90                                          | 84                                            | 87                                       | 91                                            |
| 6th             | 23             | 88                                          | 83                                            | 88                                       | 91                                            |

Notes: Numbers in these columns indicate the mean percentage of CPT-11 and S-1 actually administered as a function of normal full dosage for all patients beginning a given cycle of treatment, and the percent of patients receiving more than 80% of the normal full dosage for that cycle, respectively.
Since our concept of this new combination schedule consisted of inhibition of tumor angiogenesis and cytotoxic activity, optimal biological doses of cytotoxic agents should be determined using both toxicity and surrogate marker for antiangiogenesis such as CEPs. Moreover, antitumor efficacy of the new schedule may be significantly increased when administered in combination with bevacizumab, an antiangiogenic biologic that is used worldwide for colorectal cancer.

Another advantage of our regimen is the interval of administration of CPT-11 and S-1. The in vitro studies have shown that CPT-11 downregulates thymidylate synthase expression in tumor cells leading to synergy between CPT-11 and 5-FU that was maximal when CPT-11 was given 24 hours prior to 5-FU. Therefore, the weekly administration of CPT-11 followed by S-1 with a 2-day interval in our regimen seems to be reasonable in terms of the cytotoxic activity and of gastrointestinal toxicity such as anorexia, fatigue, and neutropenia (data not shown). Patients who had moderate anorexia or diarrhea, treatment with S-1 was temporarily discontinued. Consequently, grade 2 of either neutropenia or leukocytopenia was the most common reason for skipping the day 15 dose of CPT-11 in the treatment cycle. However, it was rare that the start of the next treatment cycle was delayed. Neutropenia, diarrhea, nausea, and vomiting frequently occurred in previous studies of combined treatment with CPT-11 plus infusional 5-FU/LV or with metronomic administration of CPT-11.

The low toxicity in the present study has resulted in higher relative dose intensity. The mean relative dose intensity of both S-1 and CPT-11 exceeded 90% up to 6th cycle. The relative dose intensity of S-1 and CPT-11 in our study was higher than that of combination therapy with metronomic administration of S-1.
and MTD administration of CPT-11.\textsuperscript{15} In Tsunoda’s regimen,\textsuperscript{16,35} S-1 was administered twice daily for 3 weeks in combination with MTD administration of CPT-11 on days 1 and 15 of a 5-week cycle. The recommended dose was 80 mg/m$^2$ of CPT-11. The dose intensity of CPT-11 in a 5-week schedule was very similar to that with Goto’s regimen.\textsuperscript{15} These findings suggest that the use of higher doses of CPT-11 would probably require a lower dose of S-1 or temporary discontinuation of S-1 to control toxicity, especially neutropenia, diarrhea, or prolonged fatigue, within acceptable levels.

Capecitabine is a widely used oral fluoropyrimidine derivative. Studies of a combination of capecitabine plus CPT-11 have shown significant efficacy, response rates ranging from 47\% to 61\%, and a median PFS or TTP of 6.1 to 8.3 months in patients with colorectal cancer.\textsuperscript{36,37} However, the incidence of grade 3 or 4 diarrhea with capecitabine plus CPT-11 was greater than 20\%, clearly higher than that with our study and other regimens with S-1 and CPT-11. Both CPT-11 and capecitabine are metabolized by carboxylesterases in the liver to an active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN-38), and to an intermediate metabolite, 5′-deoxy-5-fluoropyrimidine, respectively. The complex metabolism of both capecitabine and CPT-11 can thus theoretically lead to pharmacokinetic drug-drug interactions.\textsuperscript{38} In contrast, a previous phase I trial using S-1 and CPT-11 showed no change in the plasma concentrations of 5-FU, FBAL, or SN-38 as compared with the concentrations after administration of S-1 or CPT-11 alone.\textsuperscript{39} When CPT-11 is combined with S-1, it may, therefore, be safer and more convenient than a combination of capecitabine and CPT-11.

**Conclusion**

New combination chemotherapy using daily S-1 and low-dose weekly CPT-11 appeared to be an effective, well-tolerated, and convenient regimen in patients with advanced colorectal cancer. Our findings suggest that this new combination chemotherapy is a promising regimen, offering benefits in terms of safety and survival as compared with conventional regimens. Future studies must objectively confirm that the new S-1 and CPT-11 combination therapy can replace the standard FOLFIRI without negatively affecting efficacy or safety.

**Acknowledgements**

We are indebted to the physicians and all other medical staff who contributed to this study.

**Funding**

This work was supported by a Grant-in-Aid for Scientific Research (C) (No. 20591597) from the Ministry of Education, Culture, Sports, Science and Technology, of Japan.

**Author Contributions**

The principal investigator: KS. Responsible for study concept and design: YO. Provided patients: YO, TT, YA, NI, YT, KM, MI, SS, and AK. Collected and analyzed the data: YO, YA, and NI. Interpreted the data: YO, YA, and KS. Wrote the manuscript: YO. All authors reviewed and approved the final manuscript.

**Competing Interests**

Author(s) disclose no potential conflicts of interest.

**Disclosures and Ethics**

As a requirement of publication author(s) have provided to the publisher signed confirmation of compliance with legal and ethical obligations including but not limited to the following: authorship and contributorship, conflicts of interest, privacy and confidentiality and (where applicable) protection of human and animal research subjects. The authors have read and confirmed their agreement with the ICMJE authorship and conflict of interest criteria. The authors have also confirmed that this article is unique and not under consideration or published in any other publication, and that they have permission from rights holders to reproduce any copyrighted material. Any disclosures are made in this section. The external blind peer reviewers report no conflicts of interest.

This phase II study was conducted to validate the antitumor efficacy and safety of a new combination schedule of weekly low-dose irinotecan and daily S-1. The new combination schedule is an effective, less toxic, and convenient regimen in patients with advanced colorectal cancer.

**References**

1. Shimada Y, Yoshino M, Wakuui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. *J Clin Oncol*. 1993;11:909–13.
2. Rothenberg ML, Cox JV, DeVore RF, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. *Cancer*. 1999;85:786–95.

3. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. *N Engl J Med*. 2000;343:905–14.

4. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. *Lancet*. 2000;355:1041–7.

5. de Gramont A, Figer A, Seymour M, et al. Leucovorin for metastatic colorectal cancer. *Lancet Oncol*. 2009;10:1972–7.

6. Shirasaka T, Nakano K, Takechi T, et al. Antitumor activity of 1 M tegafur–0.4 M 5-chloro-2,4-dihydroxypyridine–1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. *Cancer Res*. 1996;56:2602–6.

7. Takechi T, Nakano K, Uchida J, et al. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. *Cancer Chemother Pharmacol*. 1997;39:205–11.

8. Kato T, Shimamoto Y, Uchida J, et al. Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil. *Anticancer Res*. 2001;21:1705–12.

9. Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. *Cancer*. 1993;71:493–509.

10. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. *Cancer Res*. 1993;53:4004–9.

11. Takechi T, Fujisaka A, Matsushima E, et al. Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydrodipyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. *Eur J Cancer*. 2002;38:1271–7.

12. Ohtsu A, Baba H, Sakata Y, et al. Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. *Br J Cancer*. 2000;83:141–5.

13. Shirasaka T, Ohtsu A, Takekada H, et al. Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. *Cancer*. 2004;100:2355–61.

14. Van den Brande J, Schöffski P, Schellens JH, et al. EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. *Br J Cancer*. 2003;88:648–53.

15. Goto A, Yamada Y, Yasui H, et al. Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. *Ann Oncol*. 2006;17:968–73.

16. Tsunoda A, Yasuda N, Nakao K, et al. Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. *Oncology*. 2009;77:192–6.

17. Yoshikawa T, Kato S, Gamoh M, et al. Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer. *Br J Cancer*. 2009;101:1972–7.

18. Iwasa S, Yamada Y, Kato K, et al. Long-term results of a phase II study of S-1 plus irinotecan in patients with advanced colorectal cancer. *Ann Oncol*. 2006;17:968–73.

19. Komatsu Y, Yuki S, Sogabe S, et al. Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSSG0302). *Oncology*. 2011;80:70–5.

20. Muro K, Boku N, Shimada Y, et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). *Lancet Oncol*. 2010;11:853–60.

21. Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: hemotherapeutics as antiangiogenics. *J Clin Oncol*. 2001;19:1195–206.

22. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. *Nat Rev Cancer*. 2004;4:423–36.

23. Ogata Y, Sasatomi T, Akagi Y, Ishibashi N, Mori S, Shirouzu K. Dosage escalation study of S-1 and irinotecan in metronomic chemotherapy against advanced colorectal cancer. *Kurume Med J*. 2009;56:1–7.

24. Therasse P, Arbuck SG, Eisenhauer EA, et al; European Organization for Research and Treatment of Cancer. European Cancer Organization: New guidelines to evaluate the response to treatment in solid tumors. *J Natl Cancer Inst*. 2009;102:205–16.

25. Pant C. New options and old dilemmas in the treatment of patients with advanced colorectal cancer. *Ann Oncol*. 2004;15:1453–9.

26. Tournigand C, André T, Achille E, et al. FOLFOX 6 or the reverse sequence in advanced colorectal cancer: A randomized GER-COR study. *J Clin Oncol*. 2004;22:229–37.

27. Colucci G, Gubbia V, Paolotti G, et al. Phase III randomized controlled trial of FOLFIRI versus FOLFOX in the treatment of advanced colorectal cancer: a multicenter study of the gruppo oncologico dell’italia meridionale. *J Clin Oncol*. 2005;23:4866–75.

28. Köhne CH, van Cutsem E, Wils J, et al; European Organisation for Research and Treatment of Cancer Gastrointestinal Group. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organization for Research and Treatment of Cancer Gastrointestinal Group Study 40986. *J Clin Oncol*. 2005;23:4856–65.

29. Murakami H, Ogata Y, Akagi Y, Ishibashi N, Shirouzu K. Circulating endothelial progenitor cells in metronomic chemotherapy using irinotecan and/or bevacizumab for colon carcinoma: Study of their clinical significance. *Exp Ther Med*. 2011;2:595–600.

30. Munoz K, Man S, Shaked Y, et al. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. *Cancer Res*. 2006;66:3386–91.

31. Duda DG, Cohen KS, di Tomaso E, et al. Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. *J Clin Oncol*. 2006;24:1449–53.

32. Whyte S, Pandor A, Stevenson M, Rees A. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer. *Health Technol Assess*. 2010;14(Suppl 2):47–53.

33. Guichard S, Hennebelle I, Bugat R, Canal P. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. *Biochem Pharmacol*. 1998;55:667–76.

34. Torigoe S, Ogata Y, Matono K, Shirouzu K. Molecular mechanisms of sequence-dependent antitumor effects of SN-38 and 5-fluorouracil combination therapy against colon cancer cells. *Anticancer Res*. 2009;29:2083–9.

35. Tsunoda A, Yasuda N, Nakao K, et al. Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. *Oncology*. 2005;72:58–63.

36. Bajetta E, Di Bartolomeo M, Mariani L, et al; Italian Trials in Medical Oncology (I.T.M.O.) Group. Randomized multicenter phase II trial of two different schedules of irinotecan combined with capcitabine as first-line treatment in metastatic colorectal carcinoma. *Cancer*. 2004;100:279–87.

37. Patt YZ, Liebmann J, Diamandidis D, et al. Capcitabine (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): Final safety findings from a phase II trial. [Abstract]. *J Clin Oncol*. 2004;22(14S):271.

38. Rea DW, Nortier JW, Ten Bokkel Huinink WW, et al. A phase I/II and pharmacokinetics study of irinotecan in combination with capcitabine as first-line therapy for advanced colorectal cancer. *Ann Oncol*. 2005;16:1123–32.

39. Yamada Y, Yasui H, Goto A, et al. Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer. *Int J Clin Oncol*. 2003;8:374–80.